TABLE 3.
Summary of Pharmacokinetic Parameters (Serum) of Bapineuzumab
| Bapineuzumab | Variables | Cmax (μg/mL) | tmax* (h) | AUC (μg×h/mL) | t½ (d) | Cl (mL/h/kg) | Vss (mL/kg) | MRT (d) |
|---|---|---|---|---|---|---|---|---|
| 0.5 mg/kg | Mean ± SD | 7.51 ± 1.41 | 1.75 (0.95–2.00) | 2716 ± 462 | 24.0 ± 4.0 | 0.190 ± 0.040 | 147 ± 27.4 | 32.8 ± 7.54 |
| n = 6 | % CV | 18.8 | 17 | 16.7 | 21.1 | 18.6 | 23.0 | |
| 1.5 mg/kg | Mean ± SD | 45.7 ± 6.59 | 1.53 (1.00–6.00) | 15,890 ± 3950 | 21.0 ± 1.53 | 0.099 ± 0.023 | 69.7 ± 10.1 | 30.2 ± 6.13 |
| n = 6 | % CV | 14.4 | 24.9 | 7.3 | 23.0 | 14.4 | 20.3 | |
| 5 mg/kg | Mean ± SD | 114 ± 29.9 | 1.31 (0.50–6.00) | 38,993 ± 5008 | 26.1 ± 4.96 | 0.130 ± 0.016 | 116 ± 17.1 | 33.8 ± 6.75 |
| n = 10 | % CV | 26.1 | 12.8 | 19.0 | 12.2 | 14.7 | 20.0 |
*
Median and range are provided for tmax.
AUC indicates area under the concentration-versus-time curve; Cl, systemic clearance; Cmax, peak concentration; CV, coefficient of variation; MRT, mean residence time; SD, standard deviation; t½, terminal phase elimination half-life; tmax, time to peak concentration; Vss, apparent steady-state volume of distribution.